Literature DB >> 31392141

Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Randall J Brenneman1, Edward Soffen2, Hiram A Gay1, Peter F Orio3,4, John P Christodouleas5, John C Baumann2, Brian C Baumann1,6.   

Abstract

Entities:  

Year:  2019        PMID： 31392141      PMCID： PMC6642965          DOI： 10.21037/tau.2019.03.14

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  25 in total

1.  Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants.

Authors:  Sabeena Sidhu; W James Morris; Ingrid Spadinger; Mira Keyes; Michelle Hilts; Robert Harrison; Karl Otto; Michael McKenzie; Alexander Agranovich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

2.  Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.

Authors:  Ryan J Burri; Nelson N Stone; Pam Unger; Richard G Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-01       Impact factor: 7.038

3.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer.

Authors:  Michael J Zelefsky; Victor E Reuter; Zvi Fuks; Peter Scardino; Alison Shippy
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

4.  Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

Authors:  Chien Peter Chen; Vivian Weinberg; Katsuto Shinohara; Mack Roach; Marc Nash; Alexander Gottschalk; Albert J Chang; I-Chow Hsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

5.  Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.

Authors:  Paul L Nguyen; Ming-Hui Chen; Anthony V D'Amico; Clare M Tempany; Graeme S Steele; Michele Albert; Robert A Cormack; David L Carr-Locke; Ronald Bleday; W Warren Suh
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

6.  Underutilization of local salvage therapy after radiation therapy for prostate cancer.

Authors:  Henry Tran; Jaime Kwok; Tom Pickles; Scott Tyldesley; Peter C Black
Journal:  Urol Oncol       Date:  2014-03-12       Impact factor: 3.498

7.  Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.

Authors:  Brandon A Mahal; David R Ziehr; Andrew S Hyatt; Emily H Neubauer-Sugar; Desmond A O'Farrell; Michael P O'Leary; Graeme S Steele; Thomas R Niedermayr; Clair J Beard; Neil E Martin; Peter F Orio; Anthony V D'Amico; Phillip M Devlin; Paul L Nguyen
Journal:  Brachytherapy       Date:  2014-05-28       Impact factor: 2.362

8.  Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.

Authors:  David S Aaronson; Ichiro Yamasaki; Alexander Gottschalk; Joycelyn Speight; I-Chow Hsu; Barby Pickett; Mack Roach; Katsuto Shinohara
Journal:  BJU Int       Date:  2009-02-23       Impact factor: 5.588

9.  Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.

Authors:  Iván Henríquez; Gemma Sancho; Asunción Hervás; Benjamin Guix; Joan Pera; Cristina Gutierrez; Oscar Abuchaibe; Rafael Martínez-Monge; Alejandro Tormo; Alfredo Polo
Journal:  Radiat Oncol       Date:  2014-04-30       Impact factor: 3.481

10.  A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.

Authors:  Yoshiya Yamada; Marisa A Kollmeier; Xin Pei; Chu Cheng Kan; Gil'ad N Cohen; Sherri M Donat; Brett W Cox; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2013-12-25       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.